IGC — India Globalization Capital Inc
NYSE MKT · Healthcare · Biotechnology
$0.30
+$0.01 (+2.19%)
India Globalization Capital Inc (IGC) is a biotechnology company listed on NYSE MKT. It is led by Ram Mukunda, based in 10224 Falls Road, Potomac, MD, United States, 20854, with about 70 employees. IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease in India, the United States, and Colombia. The company's lead product is IGC-AD1, which is in Phase 2 clinical trial for the treatment of agitation in dementia due to Alzheimer's; and TGR-63, IGC-M3, and LMP that are in pre-clinical stage for the treatment of Alzheimer's disease. It also develops IGC-1A and IGC-1C which are in pre-clinical stage for the treatment of metabolic disorders and Alzheimer's disease. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Latest reported IGC revenue for 2025-09-30 was $191.0K. Net income was -$1.8M. Revenue was down 41.8% from 2025-06-30 to 2025-09-30. IGC currently screens at market cap $24.1M.
Use this IGC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IGC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IGC SEC filings page. Lician reads the product cache first so this HTML stays unique to India Globalization Capital Inc even when a live quote feed is slow.
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease in India, the United States, and Colombia. The company's lead product is IGC-AD1, which is in Phase 2 clinical trial for the treatment of agitation in dementia due to Alzheimer's; and TGR-63, IGC-M3, and LMP that are in pre-clinical stage for the treatment of Alzheimer's disease. It also develops IGC-1A and IGC-1C which are in pre-clinical stage for the treatment of metabolic disorders and Alzheimer's disease. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
IGC Key Statistics
Market Cap
$24.10M
Volume
445,283
Previous Close
$0.30
Day Range
$0.30 – $0.31
EPS
-$0.09
Revenue
$1.27M
Net Income
-$7.12M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-5.5%
Profit Margin
-560.3%
Employees
70
IGC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $1.27M | $1.34M | $911.00K | $397.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.12M | -$13.00M | -$11.51M | -$15.02M |
| EPS (Diluted) | -$0.09 | -$0.22 | $0.00 | $0.00 |
Total Assets
$8.75M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$405.00K
Operating Cash Flow
-$4.79M
Free Cash Flow
$0.00
India Globalization Capital Inc Company Information
- President, CEO & Director
- Ram Mukunda
- Headquarters
- 10224 Falls Road, Potomac, MD, United States, 20854
- Website
- igcpharma.com
- Phone
- 301 983 0998
- IPO / Founded
- 2006-04-13
- Sector
- Healthcare
- Industry
- Biotechnology